Background: HIV-associated neurologic disorders (HAND) continue to develop in many patients with HIV. CSF amyloid measurements in HAND have been reported to be similar to those in dementia of the Alzheimer type (DAT). Confirmatory evaluation of this finding in carefully evaluated subjects is needed.
HIV-associated neurocognitive disorders (HAND) continue to be a problem in HIV-infected (HIVϩ) subjects despite generally successful virologic control with modern antiretroviral agents. The pathophysiology of observed deficits in HAND is incompletely understood, but appears to be enhanced by aging, consistent with an interaction of aging seen for other neurodegenerative processes. 1 Measurements of CSF ␤-amyloid (1-42) (A␤42), total tau (t-tau), and phosphorylated tau (p-tau181) in advanced HAND, Alzheimer disease (AD), and age-matched seronegative controls have been reported previously. 2 HAND subjects had significantly decreased CSF A␤42 and increased t-tau and p-tau181 concentrations similar to patients with AD, suggesting that HAND may be associated with AD or an AD-like process. Additional observations linking HAND and amyloid-associated processes include reports of neuropatho-logic evidence of amyloid deposition in the brains of HIVϩ patients, 3 of more silver stained (i.e., neuritic) amyloid plaques in HIVϩ patients than in controls of the same age, 4 and a demonstration of increased diffuse plaques in HIV brains. 5 It has been demonstrated that in neural cell membranes from human brain aggregates, the HIV-1 transactivator regulatory protein Tat may inhibit neprolysin, an endonuclease for A␤ breakdown, the primary peptide constituent of amyloid in AD. 5 Given the expanding insights for therapeutics to address abnormal A␤ metabolism in AD, clear demonstration of the role of similar pathophysiologic properties in HAND could be of substantial importance. Previous reports 2 are provocative, but incomplete since this article did not report A␤40, which specifically remains normal when A␤42 declines in AD. 6 Specific reductions in CSF A␤42 have been shown to be associated with brain amyloid deposition as evidenced by PET imaging of the amyloid-binding agent Pittsburgh Compound B. 7 The interpretation of decreased levels of CSF A␤42 as being due to possible AD processes would be different in the face of concomitant decreases in A␤40. Further, the findings of the previous report 2 regarding tau levels in HAND are at variance to several prior studies. 8, 9 In the present study, we compared CSF values of A␤ and tau within long-term infected HIVϩ subjects with known cognitive status to age-matched HIV uninfected controls and patients diagnosed with mild dementia of the Alzheimer type (DAT).
METHODS Subjects. CSF from clinically characterized
HIVϩ patients was obtained from both the National Neu-roAIDS Tissue Consortium (NNTC) and from the Washington University in St. Louis cohort of the CNS Highly Activated Retroviral Therapy Effects Research (CHARTER) study. All subjects gave written informed consent under the direction of the local institutional review boards for human studies. For both cohort studies from which data were used, all subjects had neuropsychometric and neurologic examinations leading to classification of cognitive impairment. NNTC subjects were enrolled due to advanced HIV disease with anticipated imminent death. All 41 CSF samples from the NNTC cohort had HAND, either classified as HIV-associated dementia (HAD) (n ϭ 11) or mild cognitive disorder (MCD) (n ϭ 30), both of which require impaired performance on a broad neuropsychometric battery and evidence of functional impairment. Within the CHARTER co-hort, an additional 8 subjects had HAND, with the rest (n ϭ 21) having normal performance on concurrent neurologic examination and neuropsychometric testing. Diagnostic classification of HAND is not made in the face of serious comorbid conditions that might be alternative explanations for neurocognitive performance deficits.
Controls were derived from a clinically well-characterized group of adults volunteering for evaluation at the Washington University Memory and Aging Project. Careful examination and testing was performed with participants categorized by the Clinical Dementia Rating (CDR) scale as unimpaired (CDR ϭ 0) or having mild impairment that has a high correlation with histologic AD in subsequent neuropathologic examinations (CDR ϭ 0.5). 6 CSF handling and evaluation. CSF samples obtained from the NNTC had been rapidly frozen and stored and shipped frozen to Washington University for analysis. The control samples were placed on ice immediately during the lumbar puncture, and stored frozen until time of analysis. HIV samples were also quickly frozen and thawed only once for the analysis. Control and DAT samples were collected at 7:30 AM, while the times of collection for the HIV samples were random daytime hours.
CSF samples were analyzed for total tau, phospho-tau 181 (p-tau181), and A␤ 42 by commercial ELISA (Innotest, Innogenetics, Ghent, Belgium), and A␤ 40 by ELISA as previously described by Fagan et al. 7 For all measures, samples were continuously kept on ice, and assays were performed on sample aliquots after a single thaw following initial freezing.
Statistical analysis.
Standard descriptive statistics were calculated for each population in the study. CSF A␤42 and A␤40 measurements were log transformed to approximate a normal distribution. CSF tau and p-tau181 required log-log transformation to approximate a normal distribution. Contrasts of biomarker measurements among the control, DAT, HIV, and HAND groups were performed using analysis of covariance after adjusting for age. p Values for pairwise comparisons were taken from the least squares means difference matrix with a significant difference if p Ͻ 0.05. Correlations among CD4, nadir CD4, plasma viral load, and CSF viral load were calculated using Pearson correlation coefficient. All statistical analyses were performed using SAS version 9.1. Table 1 provides demographic variables for neurologically normal HIV-positive patients, HAND subjects, DAT subjects, and nondemented controls. Overall, the DAT cohort was older than any other group (for all contrasts p Ͻ 0.0001). We dealt with this difference in age by including age as a covariate in the analyses. Most patients with HIV, but not all, were taking antiretroviral therapy. Within the HIVϩ subgroups, HAND patients had a trend toward lower nadir and current CD4 counts and higher plasma viral loads than cognitively normal HIVϩ patients. However, none of the differences is significant. Median CSF viral load was higher in the neurologically normal HIVϩ subjects. CSF biomarkers results are presented in table 2 and demonstrated in the figure. CSF A␤42 in the HAND HIV group was significantly lower than unaffected controls or neurologically normal HIVϩ subjects. Even after statistical corrections for the differences in age between DAT and HAND subjects, the CSF A␤42 levels in HAND subjects are not significantly different from CSF A␤42 levels in DAT subjects ( p ϭ 0.25). CSF A␤40 levels were similar for all groups. In contrast, CSF tau and p-tau181 (the primary constituents of neurofibrillary tangles in AD) for both neurologically normal and HAND HIVϩ groups were slightly lower than unaffected controls, and did not mirror the significant elevations typically seen with DAT ( figure) .
RESULTS
We also sought to identify possible associations of the biomarker findings with important measures of the biology of HIV disease including current CD4 count, nadir CD4 count, current plasma viral load, and current CSF viral load. Pearson correlation coefficients were derived and revealed no significant correlations of any single HIV disease markers to any of the 4 AD biomarkers we studied (table 3) . DISCUSSION In clinically well-characterized subjects, we find that HIV-positive subjects with neurocognitive impairment have significantly lower CSF A␤42 than unimpaired subjects, comparable to findings in mild DAT. However, we find that the tau elevations characteristic of DAT are absent in HAND. Our findings suggest that there is a change in A␤42 metabolism occurring with the development of HIV-associated neurologic dysfunction.
Age-related changes in A␤42 do not account for differences since the HAND and control populations had similar ages, and all analyses include age as a covariate. The observed reduction in CSF A␤42 in cognitively impaired HIV-positive patients is consistent with an earlier report 2 and, in the absence of reductions in CSF A␤40, suggests that the reductions in A␤42 may be indicative of brain amyloid deposition and not just death of neurons. However, in contrast to an earlier report, 2 and consistent with other studies, 8, 9 we observed that CSF tau and p-tau181 were not elevated in association with reductions in CSF A␤42. This CSF profile helps distinguish HIV from DAT, implicating abnormalities in amyloid metabolism in HAND, with no evidence of the tauopathy that occurs in DAT. Another recent report 10 shows similar findings with regard to A␤42, associating lower CSF A␤42 but normal p-tau181 with symptomatic HIV-associated cognitive disease. However, this report continues to suggest total tau was elevated in CSF of this population. The reason for the disparity in tau measurements is unclear, although one possible difference is that these patients were untreated for HIV, whereas our symptomatic patients were generally taking antiretroviral therapy. It is possible that participants in this study may have had more active or ongoing neuropathology due to lack of HIV treatment. However, this report of normal tau in the DAT patients is also discordant with AD literature. Together, our findings suggest that measurements of certain tau species in CSF may be useful as a means of differentiating HIV-associated cognitive decline from AD. Because of the aging of the HIV-positive population, this distinction may well be of increasing utility.
Further consideration of the reasons for low CSF A␤42 in HAND require ongoing research. Reductions in CSF A␤42 levels have been shown to be a reliable marker for brain amyloid deposition in patients with AD as well as a subset of cognitively normal elderly individuals hypothesized to have "preclinical" AD (i.e., amyloid deposition prior to Control without dementia (Control), mild (Clinical Dementia Rating 0.5/1.0) dementia of the Alzheimer type (DAT), neurocognitively normal HIV-positive (HIV), and neurocognitively impaired HIV-associated neurologic disorder (HAND) samples are shown. the onset of clinical dementia symptoms). [11] [12] [13] [14] While the pathology of HAND and AD differs significantly, 15 it will be important to see if PET amyloid imaging in vivo can distinguish these forms of dementia despite the similarity of the CSF A␤42 levels. We assume that in HIV, if amyloid deposition is occurring, there will be a much greater percentage of diffuse, nonfibrillar A␤ deposits as compared to what is typically seen in AD, given the absence of florid amyloid plaques in HIV neuropathology. There are reasons that could explain altered A␤ metabolism in HIV disease. HIV Tat protein has been shown to inhibit an A␤ cleaving protein, neprilysin, which could lead to increased brain amyloid deposition. 5 Alternatively, HIV Tat may compete with the amyloid precursor protein (APP) and apolipoprotein E (an A␤ chaperone) for binding to the low density lipoprotein receptor related protein (LRP), thus blocking LRP-mediated clearance of A␤ from brain interstitial fluid to peripheral compartments. 16 On the other hand, soluble APP cleavage products (sAPP␣ and sAPP␤) have been reported to be reduced in the CSF of patients with HAND compared to those with DAT or HIV-negative controls, with sAPP␣ showing a slight decline in the asymptomatic HIV state. 17 These findings, in conjunction with the low A␤42 in HIV, might suggest that synthesis of the amyloid precursor (APP) declines with symptomatic disease. If APP synthesis were decreased, one would expect a decrease in CSF A␤40 and A␤42, not just a selective decrease in A␤42. However, this idea could be tested since A␤ turnover is quite a dynamic process, approximating 8% turnover per hour, 18 and could be assessed directly.
Our findings reinforce the importance of understanding the significant change in amyloid metabolism that is associated with symptomatic HIV-associated neurologic disease and may expand considerations of the pathophysiology of HAND. The failure of HIV viral load and CD4 counts to correlate with development of HAND in our HIV-positive patients reinforces the need for reliable predictive biomarkers for this widespread problem. While CSF viral load was previously re- lated to development of dementia, in the current treatment era this is no longer the case, as we found in this analysis. 19, 20 Successful HIV therapy is resulting in long survival of patients with HIV, who are now entering age brackets where AD becomes more common. In aging patients developing dementia, our findings suggest that CSF tau measurements are likely to distinguish patients with HAND from those with AD. While age was included as a covariate in our analyses to account for agerelated changes, it may be necessary to confirm that CSF tau distinguishes HAND from DAT once a substantial sample of older patients with HAND comparable in age to DAT samples are available for analysis. Meanwhile, emerging technologies such as assessment of amyloid deposition in the brain with PET imaging and defining the dynamics of A␤ production and elimination may clarify the basis for the changes being observed.
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